Lyme disease (LD) is the most commonly reported tick-borne illness in North America. To improve LD surveillance, we explored claims data as an adjunct data source for monitoring trends in Lyme disease incidence.
Methods:
We retrospectively analyzed claims from a nationwide US health insurance plan, identifying patients with newly diagnosed LD in 13 high-prevalence states over two time periods, 2004–2006 and 2010–2012.
Results:
The average LD case incidence as estimated by using claims data in 2010–2012 (75.67 per 100,000 person-years, n = 3474) was 1.50 times higher than 2004–2006 (50.25 per 100,000 person-years, n = 1965) (p < 0.001) and higher than incidence reported by the states to the Centers for Disease Control and Prevention. Among the 13 highest-prevalence states, there were 11 states with increased LD incidence over time.
Conclusions:
Surveillance systems should explore a fusion of data sources, including payer claims that appear to be highly sensitive with limitations, with electronic laboratory data that afford high specificity, but appear to miss cases.
Get full access to this article
View all access options for this article.
References
1.
Allen-DickerJ, KlompasM. Comparison of electronic laboratory reports, administrative claims, and electronic health record data for acute viral hepatitis surveillance. J Public Health Manag Pract, 2012; 18:209–214.
2.
BaconRM, KugelerKJ, MeadPS, Centers for Disease Control and Prevention. Surveillance for Lyme disease—United States, 1992–2006. MMWR Surveill Summ, 2008; 57:1–9.
3.
BaileyTC, CarvalhoMS, LapaTM, SouzaWV, et al.Modeling of under-detection of cases in disease surveillance. Ann Epidemiol, 2005; 15:335–343.
4.
BrandaJA, Aguero-RosenfeldME, FerraroMJ, JohnsonBJB, et al.2-Tiered antibody testing for early and late lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis, 2010; 50:20–26.
5.
BrattonRL, WhitesideJW, HovanMJ, EngleRL, et al.Diagnosis and treatment of Lyme disease. Mayo Clin Proc, 2008; 83:566–571.
6.
Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep, 1995; 44:590–591.
7.
Centers for Disease Control and Prevention. Lyme Disease Data. 2013. Available at www.cdc.gov/lyme/stats/
8.
CoyleBS, StricklandGT, LiangYY, PeñaC, et al.The public health impact of Lyme disease in Maryland. J Infect Dis, 1996; 173:1260–1262.
9.
DoyleTJ, GlynnMK, GrosecloseSL. Completeness of notifiable infectious disease reporting in the United States: An analytical literature review. Am J Epidemiol, 2002; 155:866–874.
10.
HinckleyAF, ConnallyNP, MeekJI, JohnsonBJ, et al.Lyme disease testing by large commercial laboratories in the United States. Clin Infect Dis, 2014; ciu397.
11.
JohnsonL, AylwardA, StrickerRB. Healthcare access and burden of care for patients with Lyme disease: A large United States survey. Health Policy, 2011; 102:64–71.
12.
JonesSG, CoulterS, ConnerW. Using administrative medical claims data to supplement state disease registry systems for reporting zoonotic infections. Am Med Inform Assoc, 2013; 20:193–198.
13.
KlempnerMS, HuLT, EvansJ, SchmidCH, et al.Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med, 2001; 345:85–92.
14.
KlempnerMS, BakerPJ, ShapiroED, MarquesA, et al.Treatment trials for post-Lyme disease symptoms revisited. Am J Med, 2013; 126:665–669.
15.
MarderE, GarmanK, JonesTF, DunnJ, et al.Assessment of administrative claims data for public health reporting of Salmonella in Tennessee. J Am Med Inform Assoc, 2015; 22:e34–e38.
16.
McCarthyN, GieseckeJ. Case-case comparisons to study causation of common infectious diseases. Int J Epidemiol, 1999; 28:764–768.
17.
MeekJI, RobertsCL, SmithEV, CartterML. Underreporting of Lyme disease by Connecticut physicians, 1992. J Publ Health Manag Pract, 1996; 2:61–65.
18.
MorSM, DeMariaA, NaumovaEN. Hospitalization records as a tool for evaluating performance of food- and water-borne disease surveillance systems: A Massachusetts case study. PLoS One, 2014; 9:e93744.
19.
MullerI, FreitagMH, PoggenseeG, ScharnetzkyE, et al.Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: A retrospective model analysis. Clin Dev Immunol, 2012; 2012:595427.
20.
NelsonC, SahaS, ShankarM, KugelerK, et al. Epidemiology & clinical characteristics of Lyme disease diagnosed by health care providers: Analysis of a large insurance database. The 13th International Conference on Lyme Borreliosis and other Tick-Borne Diseases. Boston, MA, 2013.
21.
RamseyAH, BelongiaEA, ChyouP-H, DavisJP. Appropriateness of Lyme disease serologic testing. Ann Fam Med, 2004; 2:341–344.
22.
RyanP. Establishing a Condition Era Persistence Window for Active Surveillance. Foundation for the National Institutes of Health, 2010.
23.
SchoenRT. Editorial commentary: Better laboratory testing for lyme disease: No more western blot. Clin Infect Dis, 2013; 57:341–343.
24.
ShapiroED. Lyme disease. N Engl J Med, 2014; 371:684.
25.
Sickbert-BennettEE, WeberDJ, PooleC, MacDonaldPDM, et al.Utility of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Communicable Disease Surveillance. Am J Epidemiol, 2010; 172:1299–1305.
26.
SmithRP, SchoenRT, RahnDW, SikandVK, et al.Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med, 2002; 136:421–428.
SteereAC. Lyme disease. N Engl J Med, 2001; 345:115–125.
29.
SteereAC, McHughG, DamleN, SikandVK. Prospective study of serologic tests for lyme disease. Clin Infect Dis, 2008; 47:188–195.
30.
TugwellP, DennisD, WeinsteinA, WellsG, et al.Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med, 1997; 127:1109–1123.
31.
VirnigBA, McBeanM. Administrative data for public health surveillance and planning. Annu Rev Public Health, 2001; 22:213–230.
32.
WormserGP, DattwylerRJ, ShapiroED, HalperinJJ, et al.The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis, 2006; 43:1089–1134.
